日批在线视频_内射毛片内射国产夫妻_亚洲三级小视频_在线观看亚洲大片短视频_女性向h片资源在线观看_亚洲最大网

US EUROPE AFRICA ASIA 中文
Business / Companies

GSK puts China corruption case behind it, forms new business model

By Cecily Liu (chinadaily.com.cn) Updated: 2015-10-22 20:17

GSK puts China corruption case behind it, forms new business model

The logo of GlaxoSmithKline (GSK) is seen on its office building in Shanghai in this July 12, 2013 file photo.[Photo/Agencies]

GlaxoSmithKline emerged from its corruption scandal in China in 2013 to form a new business model in the country and is committed to further expansion there, chief executive officer Andrew Witty told China Daily in London on Wednesday in an exclusive interview.

"We think it's a very sad and disappointing experience, but we've reacted constructively and learnt many things. And now we understand China better, we have a new commercial model and incentive system, which is in step with the expectations of the Chinese government," Witty said.

In 2013, GSK was found by the Chinese authorities to be bribing doctors to prescribe its drugs to patients, and after a court trial the company was made to pay a $489 million fine in 2014.

Witty said that GSK has since developed a commercial model with improved technology and transparency.

The transparency of the model allows GSK to monitor its sales staff to make sure no bribe is paid to doctors, and the continuously improving technology allows doctors to obtain much more information about GSK drugs to aid their decision making process when prescribing medicine.

"We've made it clear to the doctors in China about our changes and have spent a great deal of time to explain to them the reasons for us making the changes. We have received a lot of understanding and appreciation from doctors about our approach," Witty said.

As well, GSK has invested in continuously improving technology to reduce the cost of the medicine, Witty said.

Speaking about China's healthcare market environment, Witty said that China is a country that it takes time to understand, just like any other country, and understanding China encompasses its economic policies, economic direction and regulation.

He said that "GSK is lucky to be a guest of China" and will fulfill its responsibility to deliver the medicine that are up to expectations.

GSK also announced on Wednesday that it will invest 2 million pounds in a 3 year partnership with the National Health and Family Planning Commission of China to train seven thousand Chinese doctors in the diagnosis and treatment of Hepatitis B.

Witty said that this investment reaffirms GSK's long term commitment to serving China and the healthcare needs of patients in the country.

Hepatitis B is a high priority in China, with about 20 million sufferers across the country remaining untreated.

"We think it is important that we're doing the training in partnership with the Chinese government, so that we can make sure what we have invested in will help to address issues that are of real importance to China," said Witty.

He said that the Hepatitis B investment is similar to GSK's investment into training Chinese doctors in the treatment of respiratory conditions and chronic obstructive pulmonary disease, announced last month, which are also healthcare priority areas identified by the government.

The Hepatitis B program, to be run over three years, and delivered by the Development Center for Medical Science and Technology, National Health and Family planning Commission of China, will help doctors understand how to diagnose, treat and provide ongoing management to patients with Hepatitis B.

Witty said that China will remain important to GSK over the long term, in particular because it has a large population, meaning that from a commercial perspective the sales potential is great, and from a research perspective it can provide a valuable environment to develop medicine that GSK can use globally.

GSK was ranked as the world's sixth-largest pharmaceutical company in 2014, with revenue of 23 billion pounds.

GSK has already committed 6 million pounds for public health initiatives in China over the next five years, with around 4 million being spent on independent GP training, the company said in a statement.

To contact the reporter: cecily.liu@mail.chinadailyuk.com

Hot Topics

Editor's Picks
...
主站蜘蛛池模板: 91av在线播放| 99视频这里有精品 | 亚洲精品www久久久久久 | 国产欧美网站 | 在线观看你懂的视频 | 天天有av | 亚洲欧美v | 色欧美色 | 成人影片免费 | 日韩三级黄 | 蜜桃成人在线视频 | 一区二区欧美视频 | 男人资源av | 朝桐光x88av 国产亚洲精品久久久久久 国产免费嫩草影院 | 亚洲我射av | 日本国产欧美 | 国产绿帽刺激高潮对白 | 日韩在线毛片 | 嫩草99 | 亚洲激情综合网 | 中文无码日韩欧 | 中文字幕一区二区在线播放 | 自拍偷拍视频在线观看 | 日本久久精品 | 免费成人av片 | 亚洲人人 | 黄页网站在线播放 | 精品视频一区二区三区在线观看 | 91在线看视频 | 国产一区久久久 | 久久精品综合 | 亚洲成人99 | 日本道中文字幕 | 久草免费在线视频 | 欧美亚洲精品在线观看 | 国产一区二区三区网站 | 亚洲美女色视频 | 欧美有码在线观看 | 四虎成人精品永久免费av九九 | 国产suv精品一区二区33 | 日本久久久久久久久久 |